Geneva Capital Management LLC Has $12.83 Million Stake in Mesa Laboratories, Inc. $MLAB

Geneva Capital Management LLC reduced its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 3.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 191,386 shares of the medical instruments supplier’s stock after selling 7,706 shares during the quarter. Geneva Capital Management LLC’s holdings in Mesa Laboratories were worth $12,825,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in MLAB. BNP Paribas Financial Markets increased its holdings in shares of Mesa Laboratories by 30.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 243 shares during the last quarter. Gabelli Funds LLC lifted its holdings in Mesa Laboratories by 114.6% in the 3rd quarter. Gabelli Funds LLC now owns 53,974 shares of the medical instruments supplier’s stock worth $3,617,000 after purchasing an additional 28,818 shares during the last quarter. Gamco Investors INC. ET AL lifted its holdings in Mesa Laboratories by 109.0% in the 3rd quarter. Gamco Investors INC. ET AL now owns 8,212 shares of the medical instruments supplier’s stock worth $550,000 after purchasing an additional 4,282 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Mesa Laboratories by 1.3% during the third quarter. Dimensional Fund Advisors LP now owns 116,772 shares of the medical instruments supplier’s stock worth $7,823,000 after purchasing an additional 1,488 shares during the period. Finally, Victory Capital Management Inc. boosted its position in Mesa Laboratories by 448.0% during the third quarter. Victory Capital Management Inc. now owns 10,455 shares of the medical instruments supplier’s stock worth $701,000 after purchasing an additional 8,547 shares during the period. Institutional investors and hedge funds own 90.60% of the company’s stock.

More Mesa Laboratories News

Here are the key news stories impacting Mesa Laboratories this week:

• Positive Sentiment: Several directors bought meaningful stakes this week (Shiraz S. Ladiwala 3,500 shares ~ $72.23, R. Tony Tripeny 1,315 shares ~ $76.00, Mark C. Capone 1,301 shares ~ $76.35). Multiple insider buys at these levels signal management confidence and can be interpreted as a bullish catalyst. Read More.
• Neutral Sentiment: Mesa announced a CEO transition naming Siddhartha Kadia as President & CEO. Leadership change is material — it can drive strategic refocus but may also introduce short‑term volatility until Kadia outlines priorities and execution plans. Read More.
• Negative Sentiment: Analyst skepticism and bearish commentary raise selling pressure: a recent Seeking Alpha piece questions valuation, and summary data show a high P/E and a 100% payout ratio on dividends — factors that heighten concerns about earnings sustainability and upside at current prices. Read More.

Mesa Laboratories Price Performance

Shares of MLAB stock opened at $80.60 on Thursday. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.94 and a quick ratio of 1.45. The stock’s fifty day simple moving average is $87.40 and its 200 day simple moving average is $78.22. Mesa Laboratories, Inc. has a one year low of $55.45 and a one year high of $131.20. The firm has a market cap of $444.91 million, a price-to-earnings ratio of 125.94 and a beta of 0.85.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.41 by $0.66. The firm had revenue of $65.13 million during the quarter, compared to the consensus estimate of $63.23 million. Mesa Laboratories had a net margin of 1.51% and a return on equity of 22.02%. On average, analysts expect that Mesa Laboratories, Inc. will post 8 earnings per share for the current fiscal year.

Mesa Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 16th. Shareholders of record on Saturday, February 28th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.8%. Mesa Laboratories’s payout ratio is currently 100.00%.

Insider Activity at Mesa Laboratories

In other news, Director R Tony Tripeny bought 1,315 shares of the stock in a transaction dated Tuesday, March 10th. The stock was bought at an average cost of $76.00 per share, with a total value of $99,940.00. Following the purchase, the director owned 5,398 shares of the company’s stock, valued at approximately $410,248. This represents a 32.21% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mark Christopher Capone acquired 1,301 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were purchased at an average cost of $76.35 per share, with a total value of $99,331.35. Following the completion of the acquisition, the director directly owned 3,429 shares in the company, valued at approximately $261,804.15. The trade was a 61.14% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 6,116 shares of company stock valued at $452,076 over the last quarter. Corporate insiders own 4.90% of the company’s stock.

Wall Street Analyst Weigh In

MLAB has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Mesa Laboratories in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research note on Friday, January 9th. Wells Fargo & Company lifted their target price on shares of Mesa Laboratories from $83.00 to $94.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. Finally, Wall Street Zen raised shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 7th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Mesa Laboratories currently has a consensus rating of “Reduce” and a consensus target price of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.